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re s e a rc hb r i e f s
Prescreening Patients for
Use of Anti-Cancer Drug
Researchers at Penn Medicine and PennVet have
determined a way to pre-screen cancer patients to see if
they are suitable candidates for proteasome inhibitors, a
promising class of anti-cancer drugs.They propose to test
for p53, a well-known tumor-suppressor protein that is
broken down by cellular machinery called proteasomes.
This study appears in the June 2007 issue of Blood.
In cancer patients whose tumors do not produce p53,
proteasome inhibitors might be ineffective.This patient
group could be spared unnecessary treatment with
possible harmful side effects. On the other hand,
proteasome inhibitors are highly effective against
lymphomas that do have the ability to produce p53.
“These findings have important implications for clinical
practice,” Dr.Thomas-Tikhonenko said.“The proteosome
inhibitor bortezomib is approved by the FDA for the
treatment of multiple myeloma, another cancer of
lymphoid cells.Yet, only a fraction of multiple myeloma
patients respond to the drug.”
Gene Therapy Can Restore Vision
Gus Aguirre,V’68, professor of ophthalmology and
medical genetics, was part of a multi-institutional study
whose results demonstrated that gene therapy used to
restore retinal activity to the blind also restores function to
the brain’s visual center, a critical component of seeing.
The study, led by Geoffrey Aguirre, assistant professor of
neurology at Penn Medicine, shows that gene therapy can
improve retinal, visual-pathway and visual-cortex responses
in animals born blind and has the potential to do the same
in humans.
Findings of the study were reported in the journal
PLoS Medicine.
Skin Secretion
Linked to Parasite
Researchers from Penn
Medicine and PennVet have
found a link between some of
the most common parasites
that cause infection and disease
throughout the developing
world and their attraction to a
chemical secreted from human
and animal skin.
These skin-penetrating parasites infect more than 600
million people worldwide and contribute to anemia, ill
health and poor physical and cognitive development
among children of developing nations.
Urocanic acid, a common histidine metabolite abun-
dant in mammalian skin, attracts the parasitic nematode
Strongyloides stercoralis. But, according to researchers, the
attraction can be suppressed by metal ions, suggesting a
potential new strategy for preventing infection.
The findings were reported in the Proceedings of the
National Academy of Sciences.Drs. Gerhard Schad,
professor of parasitology;Mario Brenes, research special-
ist; and Seth Dunipace—all from the Department of
Pathobiology at PennVet.
Reversing Infertility in Cancer Patients
In the April 20 issue of Science,
Ralph Brinster,V’60, Richard
King Mellon Professor of
Reproductive Physiology, reports
methods for the recovery, culture
and transplantation of
spermatogonial stem cells.
Recovering stem cells and freezing
them at very low temperatures
(cryopreservation) can be a way to
preserve the male germ line of
valuable livestock animals, companion animals and
endangered species. Perhaps the most potentially valuable
medical application of spermatagonial stem cell (SSC)
research is for prepubertal boys undergoing chemotherapy
or irradiation for cancer. In many cases, the SSCs are
destroyed as a side effect of treatment, and the patient is
left infertile. It is possible to obtain a testicular biopsy and
cryopreserve a cell suspension produced from the biopsy.
This cell suspension containing SSCs could then be
transplanted back into the patient’s testes at any age after
treatment, potentially resulting in reversal of infertility
through renewed sperm production.
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Strongyloides stercoralis. Courtesy
of Smittskyddsinstitutet, the
Swedish Institute for Infectious
Disease Control.
Green staining depicts tumor cells dying after treatment with proteasome
inhibitors. In the left panel, the tumor lacks p53, and only a fraction of the
cells are killed. In the right panel, the tumor produces p53, resulting in mas-
sive cell death.
Image Credit: Andrei Thomas-Tikhonenko, PhD, University of Pennsylvania School of Medicine; Blood.
